查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
在線藥房 (ePharmacy)：主要趨勢、區域分析和市場預測 (2022-2027)
市場調查報告書
商品編碼
1134406

在線藥房 (ePharmacy)：主要趨勢、區域分析和市場預測 (2022-2027)

ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027
出版日期: | 出版商: Juniper Research Ltd | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球在線藥店用戶數量預計將從 2022 年的 7.95 億增長到 2027 年的 10 億，增長 28%。這一增長被認為是由於 COVID-19 大流行迫使消費者呆在家裡並通過在線藥店取藥而導致採用率激增的結果。我們預計，隨著供應商專注於通過改進在線藥店提供的效率和便利性來維持和擴大其客戶群，我們預計將繼續增長。

  • 消費者將繼續使用在線藥店，因為他們認識到在線藥店提供的藥品價格實惠以及與實體藥店相比具有更廣泛的選擇等優勢。
  • 將通過簡化在線流程來維持在線藥店的增長。這可以通過消除紙質處方來實現，因為電子處方越來越被廣泛接受。
  • 在線藥房服務將繼續大量用於非處方藥（OTC）藥品。預計2027年全球場外交易量將達到89億筆，佔全球交易總額的64%。另一方面，全球處方交易數量為 50 億。由於消費者對交付準確性、時間和錯過交付的擔憂，處方的數字化將被推遲。為了解決這些問題並抵消非法在線藥店的興起，實時跟蹤和加強對在線藥店的監管應該是確保未來增長的優先事項。

本報告分析了全球在線藥房 (ePharmacy) 市場，包括市場的基本結構、在發達國家/新興國家的滲透率、主要市場驅動因素以及整體市場規模趨勢預測（用戶數量、交易數量、金額未來五年的交易）、按行業（處方藥、OTC）和地區（共 60 個國家）的詳細趨勢、市場競爭結構、未來增長潛力和挑戰、主要公司 我們正在調查（15公司總數）。

回答的主要問題

  • 1. 主要市場趨勢將如何影響在線藥店？
  • 2. OTC（非處方藥）和處方藥之間的在線藥店有何不同？
  • 3. 在線藥房市場的主要供應商有哪些？
  • 4. 阻礙網上藥店的製約因素有哪些？
  • 5. 在線藥店在哪些地區最成功？

主要特點

  • 基準行業預測：按地區（共 8 個地區）、按國家/地區（共 60 個國家/地區）
    • 北美
      • 加拿大、美國
    • 拉丁美洲
      • 阿根廷、巴西、智利、哥倫比亞、厄瓜多爾、墨西哥、秘魯、烏拉圭
    • 西歐
      • 奧地利、比利時、丹麥、芬蘭、法國、德國、希臘、愛爾蘭、意大利、荷蘭、挪威、葡萄牙、西班牙、瑞典、瑞士、英國
    • 中歐和東歐
      • 克羅地亞、捷克共和國、匈牙利、波蘭、羅馬尼亞、俄羅斯、土耳其、烏克蘭
    • 遠東/中國
      • 中國、香港、日本、韓國
    • 印度次大陸
      • 孟加拉國、印度、尼泊爾、巴基斯坦
    • 其他亞太國家
      • 澳大利亞、印度尼西亞、馬來西亞、新西蘭、菲律賓、新加坡、泰國、越南
    • 非洲/中東
      • 阿爾及利亞、埃及、以色列、肯尼亞、科威特、尼日利亞、卡塔爾、沙特阿拉伯、南非、阿拉伯聯合酋長國

分析的公司

  • Juniper Research Competitor Leaderboard對象企業：1mg、Amazon Pharmacy、Apollo Pharmacy、CVS Health、DocMorris、Express Scripts、Giant Eagle、Lloyds Pharmacy、Netmeds、Optum、Rowlands Pharmacy、The Kroger、Walgreens Boots Alliance、Walmart、Well Pharmacy
  • 言及企業：Accredo、Adipositas Care、Adobe、Aetna、Bajaj Allianz、Bakers、Berkshire Hathaway、Blue Cross Blue Shield、Braze、CareCentrix、CareContinum、CareZone、Chefaa、City Market Food and Pharmacy、Copps、CuraScriptSD、Deliveroo、Ecrebo、Epic、Evicore Healthcare、Famhealth、FredMeyer、Freedom Fertility Pharmacy、Frys、HasHealth、Haven、HDFC、Horizon、ICICI Bank、Inside Rx、JPMorgan Chase、KiviHealth、Lazada Philippines、Lyf、Mamajan Imaging、Max Bupa、MedAvail、Medbase、Mesmerize、Microsoft、MyMatrixx、NCotably、Novo Nordisk、Omnicell、Onofre、Patanjali、PathCare、PAYBACK、PillPack、Practio、Prime Therapeutics、Raia Drogasil SA、SBI、Shopee Philippines、Signify Health、Target Pharmacies、Tata Digital、TeleClinic、Thyrocare、Verizon、Willons、Yodawy、ZEE5、Zur Rose Group.

內容

第 1 章分析概述和戰略建議

第2章現狀與展望

  • 在線藥房生態系統：概覽
    • 在線藥店的類型
      • 數字專賣店
      • 實體店的數字孿生
    • 電子處方
  • 在線藥店的好處
    • 對消費者的好處
      • 節省時間
      • 降低成本
      • 效率
      • 個性化
      • 選擇範圍
    • 對公司的好處
      • 節省時間
      • 最大化利潤
      • 對政府的好處
  • 主要市場驅動因素分析
  • 限制因素

第3章區域分析

  • 區域分析
    • 北美
      • 美國
      • 加拿大
    • 拉丁美洲
      • 墨西哥
      • 巴西
    • 西歐
      • 德國
      • 英國
    • 中歐和東歐
      • 波蘭
      • 土耳其
    • 遠東/中國
      • 中國
      • 韓國
    • 印度次大陸
      • 印度
      • 巴基斯坦
    • 亞太地區
      • 澳大利亞
      • 菲律賓
    • 非洲/中東
      • 埃及
      • 阿拉伯聯合酋長國

第 4 章競爭對手排行榜和供應商簡介

  • 在線藥房：供應商資料
    • 1mg
      • 公司
      • 地區
      • 主要客戶和合作夥伴
      • 高級產品/服務
      • JuniperResearch 洞察：主要優勢和戰略機遇
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Pharmacy
    • DocMorris
    • Express Scripts
    • Giant Eagle
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • The Kroger
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

第5章市場預測

  • 簡介
    • 在線藥房處方藥：一種預測性研究方法
    • 在線藥店的 OTC（非處方藥）：一種預測性研究方法
    • 在線藥店交易總數
    • 網上藥店的總交易額
    • 在線藥店總收入
簡介目錄

Juniper Research's “ePharmacy” report provides a detailed evaluation of the market, including the adoption of ePharmacy within both developing and established markets. In addition, this report covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of 15 leading ePharmacy vendors across the market.

The research suite also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of ePharmacy users, number of ePharmacy transactions, number of OTC (Over the Counter) and prescription transactions through ePharmacy and total ePharmacy revenue.

This research suite comprises of:

  • Strategy & Forecasts (PDF)
  • 5-year Market Sizing & Forecast Spreadsheet (Excel)
  • 12 Months Access to harvest Online Data Platform

KEY FEATURES

  • Market Dynamics: A strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of ePharmacy technologies, including the following:
    • COVID-19 impact on the ePharmacy market
    • Future strategic direction and market outlook for ePharmacy
    • Key issues ePharmacy vendors must be aware of surrounding legislation and data sharing
  • Regional Analysis: A regional-level analysis of 16 countries, spanning 8 key regions; covering the current deployment level and future outlook of ePharmacy in each market.
  • Key Takeaways & Strategic Recommendations: Analysis of key development opportunities within ePharmacies, accompanied by key strategic recommendations for stakeholders.
  • Benchmark Industry Forecasts: Includes forecasts for total number of ePharmacy users, total annual spend on ePharmacy, total fee revenue from ePharmacy, total transaction value from ePharmacy. Total number of transactions and revenue split by OTC and prescription medication. This data is split by our 8 key forecast regions and 60 countries:
    • North America:
      • Canada, US
    • Latin America:
      • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
    • West Europe:
      • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
    • Central & East Europe:
      • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
    • Far East & China:
      • China, Hong Kong, Japan, South Korea
    • Indian Subcontinent:
      • Bangladesh, India, Nepal, Pakistan
    • Rest of Asia Pacific:
      • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
    • Africa & Middle East:
      • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
  • Juniper Research Competitor Leaderboard: Key player capability and capacity assessment for 15 ePharmacy vendors:
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

KEY QUESTIONS ANSWERED

  • 1. How will key market trends affect ePharmacy?
  • 2. How will ePharmacy differ for over-the-counter and prescription medication?
  • 3. Who are the leading vendors in the ePharmacy market?
  • 4. What limitations are holding back ePharmacy?
  • 5. What regions will ePharmacy be most successful in?

COMPANIES REFERENCED

  • Included in the Juniper Research Competitor Leaderboard: 1mg, Amazon Pharmacy, Apollo Pharmacy, CVS Health, DocMorris, Express Scripts, Giant Eagle, Lloyds Pharmacy, Netmeds, Optum, Rowlands Pharmacy, The Kroger, Walgreens Boots Alliance, Walmart, Well Pharmacy.
  • Mentioned: Accredo, Adipositas Care, Adobe, Aetna, Bajaj Allianz, Bakers, Berkshire Hathaway, Blue Cross Blue Shield, Braze, CareCentrix, CareContinum, CareZone, Chefaa, City Market Food and Pharmacy, Copps, CuraScriptSD, Deliveroo, Ecrebo, Epic, Evicore Healthcare, Famhealth, FredMeyer, Freedom Fertility Pharmacy, Frys, HasHealth, Haven, HDFC, Horizon, ICICI Bank, Inside Rx, JPMorgan Chase, KiviHealth, Lazada Philippines, Lyf, Mamajan Imaging, Max Bupa, MedAvail, Medbase, Mesmerize, Microsoft, MyMatrixx, NCotably, Novo Nordisk, Omnicell, Onofre, Patanjali, PathCare, PAYBACK, PillPack, Practio, Prime Therapeutics, Raia Drogasil SA, SBI, Shopee Philippines, Signify Health, Target Pharmacies, Tata Digital, TeleClinic, Thyrocare, Verizon, Willons, Yodawy, ZEE5, Zur Rose Group.

DATA & INTERACTIVE FORECAST

Juniper Research's “ePharmacy” forecast suite includes:

  • Prescription Medication
  • Over-the-Counter Medication

Metrics including total number of transactions completed through ePharmacy, total annual spend on ePharmacy, total revenue through ePharmacy transactions, total revenue through ePharmacy fees, split by OTC and prescription medication.

  • Geographical splits: 60 countries
  • Number of tables: Over 31 tables
  • Number of datapoints: Over 23,500 datapoints
  • harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart - using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.
  • Interactive Excels (IFxl): Our IFxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. IFxls greatly increase a client's ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

The number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases through refining the efficiency and simplicity that ePharmacy provides.

  • Consumers will continue to utilise ePharmacies as they realise the benefits it provides them, including affordability of medication, and a wider range of choice compared to bricks-and-mortar pharmacies.
  • ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of their prescriptions.
  • ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027, accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

Table of Contents

1. Key Takeaways & Strategic Recommendations

  • 1.1. Key Takeaways & Strategic Recommendations
  • 1.2. Strategic Recommendations

2. Current Status & Future Outlook

  • 2.1. Overview of ePharmacy Ecosystem
    • Figure 2.1: Visualisation Showing ePharmacy Stages
    • 2.1.1. Types of ePharmacy
      • i. Digital-only Stores
      • ii. Digital Twin of Bricks-and-Mortar
    • 2.1.2. ePrescribing
      • Figure 2.2: Visualisation of ePrescribing
  • 2.2. Benefits of ePharmacy
    • 2.2.1. Benefits for Consumers
      • i. Time Saving
      • ii. Cost Savings
      • iii. Efficiency
      • iv. Personalisation
      • v. Range of Choice
    • 2.2.2. Benefits for Corporations
      • i. Time Saving
      • ii. Maximise Profit Margin
        • Figure 2.3: Visualisation Showing Benefits for Corporates
      • iii. Benefits for Governments
  • 2.3. Exploration of Key Market Drivers
  • 2.4. Limitations

3. Regional Analysis

  • 3.1. Regional Analysis
    • 3.1.1. North America
      • i. US
      • ii. Canada
    • 3.1.2. Latin America
      • i. Mexico
      • ii. Brazil
    • 3.1.3. West Europe
      • i. Germany
      • ii. UK
    • 3.1.4. East & Central Europe
      • i. Poland
      • ii. Turkey
    • 3.1.5. Far East & China
      • i. China
      • ii. South Korea
    • 3.1.6. Indian Subcontinent
      • i. India
      • ii. Pakistan
    • 3.1.7. Asia Pacific
      • i. Australia
      • ii. Philippines
    • 3.1.8. Africa & Middle East
      • i. Egypt
      • ii. United Arab Emirates

4. Competitor Leaderboard and Vendor Profiles

  • Table 4.1: Juniper Research Competitor Leaderboard: ePharmacy Vendors Included & Product Portfolio
  • Figure 4.2: Juniper Research Leaderboard: ePharmacy Vendors
  • Table 4.3: Juniper Research Leaderboard: ePharmacy Vendors & Positioning
  • Table 4.4: Juniper Research Leaderboard Heatmap: ePharmacy Vendors
  • 4.1. ePharmacy - Vendor Profiles
    • 4.1.1. 1mg
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.2. Amazon Pharmacy
      • i. Corporate Information
        • Table 4.5: Amazon's Select Financial Information ($bn), FY2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.3. Apollo Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.4. CVS Pharmacy
      • i. Corporate Information
        • Table 4.6: CVS Health Corporation's Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.5. DocMorris
      • i. Corporate Information
        • Table 4.7: Zur Rose's Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.6. Express Scripts
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.7. Giant Eagle
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.8. Lloyds Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
        • Figure 4.8: Visualisation of Lloyds Direct App
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.9. Netmeds
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.10. Optum
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.11. Rowlands Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
        • Figure 4.9: Rowlands Pharmacy Hey Pharmacist
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.12. The Kroger
      • i. Corporate Information
        • Table 4.10: Kroger's Select Financial Information ($bn), FY2020-2022 (FYE 31st January)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.13. Walgreens Boots Alliance
      • i. Corporate Information
        • Table 4.11: Walgreens Boots Alliance's Select Financial Information ($bn), FY2019-2021 (FYE 30th August)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.14. Walmart
      • i. Corporate Information
        • Table 4.12: Walmart's Select Financial Information ($bn), FY 2020-2022 (FYE 31st January)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.15. Well Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
        • Table 4.13: Juniper Research Competitor Leaderboard Scoring Criteria

5. Market Forecasts

  • 5.1. Introduction
    • 5.1.1. ePharmacy Prescription Forecast Methodology
    • 5.1.2. ePharmacy OTC Forecast Methodology
      • Figure 5.1: ePharmacy Prescription Revenue Methodology
      • Figure 5.2: ePharmacy OTC Revenue Methodology
    • 5.1.3. Total ePharmacy Transactions
      • Figure & Table 5.3: Total ePharmacy Transactions (m), Split by 8 Key Regions, 2022-2027
      • Table 5.4: Total ePharmacy Transactions, Split by Prescription and OTC Medication
    • 5.1.4. Total ePharmacy Transaction Value
      • Figure & Table 5.5: Total ePharmacy Transaction Value ($m), Split by 8 Key Regions, 2022-2027
      • Table 5.6: Total ePharmacy Transaction Value, Split by Prescription and OTC Medication
    • 5.1.5. Total ePharmacy Revenue
      • Figure & Table 5.7: Total ePharmacy Revenue ($m), Split by 8 Key Regions, 2022-2027
      • Table 5.8: Total ePharmacy Revenue ($m), Split by Prescription and OTC Medication